Adult-onset still's disease and treatment results with tocilizumab

Kır S., Özgen M., Zontul S.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, cilt.75, sa.3, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 75 Sayı: 3
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1111/ijcp.13936
  • Dergi Adı: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

Aims Adult-onset Still's disease (AOSD) is a rare and non-familial auto-inflammatory disorder. Increased levels of IL-6 and other pro-inflammatory cytokines have been shown in AOSD. To evaluate the efficacy and safety profile of tocilizumab (TCZ), an IL-6 receptor antagonist monoclonal antibody, in AOSD.